# Jabil Inc: financial statements, quarterly JBL · NYSE · CIK 898293 · [Technology](/sectors/technology.md) · fiscal year ends Aug 31 Pages: [Overview](/companies/jbl.md) · [Financials](/companies/jbl/financials.md) · [Filings](/companies/jbl/filings.md) · [Insiders](/companies/jbl/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/jbl/financials.md?period=annual). ## Income statement | Line item | Unit | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q4 FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) | Q4 FY2026 (2026-08-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $bn | [8.4](/filings/0001628280-25-001058.md) | [6.8](/filings/0001628280-25-017004.md) | [6.8](/filings/0001628280-25-033410.md) | [7.0 d](/filings/0001628280-26-067038.md) | [7.0](/filings/0001628280-26-001450.md) | [6.7](/filings/0001628280-26-024148.md) | [7.8](/filings/0001628280-26-046138.md) | [8.3 d](/filings/0001628280-26-067038.md) | [8.3](/filings/0001628280-26-001450.md) | [8.3](/filings/0001628280-26-024148.md) | [8.8](/filings/0001628280-26-046138.md) | [10.6 d](/filings/0001628280-26-067038.md) | | Cost of revenue | $bn | [7.6](/filings/0001628280-25-001058.md) | [6.1](/filings/0001628280-25-017004.md) | [6.2](/filings/0001628280-25-033410.md) | [6.3 d](/filings/0001628280-26-067038.md) | [6.4](/filings/0001628280-26-001450.md) | [6.2](/filings/0001628280-26-024148.md) | [7.1](/filings/0001628280-26-046138.md) | [7.5 d](/filings/0001628280-26-067038.md) | [7.6](/filings/0001628280-26-001450.md) | [7.5](/filings/0001628280-26-024148.md) | [7.9](/filings/0001628280-26-046138.md) | [9.6 d](/filings/0001628280-26-067038.md) | | Gross profit | $bn | [0.8](/filings/0001628280-25-001058.md) | [0.6](/filings/0001628280-25-017004.md) | [0.6](/filings/0001628280-25-033410.md) | [0.7 d](/filings/0001628280-26-067038.md) | [0.6](/filings/0001628280-26-001450.md) | [0.6](/filings/0001628280-26-024148.md) | [0.7](/filings/0001628280-26-046138.md) | [0.8 d](/filings/0001628280-26-067038.md) | [0.7](/filings/0001628280-26-001450.md) | [0.7](/filings/0001628280-26-024148.md) | [0.8](/filings/0001628280-26-046138.md) | [1.0 d](/filings/0001628280-26-067038.md) | | Research and development | $bn | [0.0](/filings/0001628280-25-001058.md) | [0.0](/filings/0001628280-25-017004.md) | [0.0](/filings/0001628280-25-033410.md) | [0.0 d](/filings/0001628280-26-067038.md) | [0.0](/filings/0001628280-26-001450.md) | [0.0](/filings/0001628280-26-024148.md) | [0.0](/filings/0001628280-26-046138.md) | [0.0 d](/filings/0001628280-26-067038.md) | [0.0](/filings/0001628280-26-001450.md) | [0.0](/filings/0001628280-26-024148.md) | [0.0](/filings/0001628280-26-046138.md) | [0.0 d](/filings/0001628280-26-067038.md) | | Selling, general and administrative | $bn | [0.3](/filings/0001628280-25-001058.md) | [0.3](/filings/0001628280-25-017004.md) | [0.3](/filings/0001628280-25-033410.md) | [0.2 d](/filings/0001628280-26-067038.md) | [0.3](/filings/0001628280-26-001450.md) | [0.3](/filings/0001628280-26-024148.md) | [0.3](/filings/0001628280-26-046138.md) | [0.2 d](/filings/0001628280-26-067038.md) | [0.3](/filings/0001628280-26-001450.md) | [0.3](/filings/0001628280-26-024148.md) | [0.3](/filings/0001628280-26-046138.md) | [0.2 d](/filings/0001628280-26-067038.md) | | Operating income | $bn | [0.3](/filings/0001628280-25-001058.md) | [1.1](/filings/0001628280-25-017004.md) | [0.3](/filings/0001628280-25-033410.md) | [0.3 d](/filings/0001628280-26-067038.md) | [0.2](/filings/0001628280-26-001450.md) | [0.2](/filings/0001628280-26-024148.md) | [0.4](/filings/0001628280-26-046138.md) | [0.3 d](/filings/0001628280-26-067038.md) | [0.3](/filings/0001628280-26-001450.md) | [0.4](/filings/0001628280-26-024148.md) | [0.4](/filings/0001628280-26-046138.md) | [0.6 d](/filings/0001628280-26-067038.md) | | Interest expense | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Income tax | $bn | [0.0](/filings/0001628280-25-001058.md) | [0.1](/filings/0001628280-25-017004.md) | [0.1](/filings/0001628280-25-033410.md) | [0.1 d](/filings/0001628280-26-067038.md) | [0.0](/filings/0001628280-26-001450.md) | [0.1](/filings/0001628280-26-024148.md) | [0.1](/filings/0001628280-26-046138.md) | [0.1 d](/filings/0001628280-26-067038.md) | [0.1](/filings/0001628280-26-001450.md) | [0.1](/filings/0001628280-26-024148.md) | [0.1](/filings/0001628280-26-046138.md) | [0.1 d](/filings/0001628280-26-067038.md) | | Net income | $bn | [0.2](/filings/0001628280-25-001058.md) | [0.9](/filings/0001628280-25-017004.md) | [0.1](/filings/0001628280-25-033410.md) | [0.1 d](/filings/0001628280-26-067038.md) | [0.1](/filings/0001628280-26-001450.md) | [0.1](/filings/0001628280-26-024148.md) | [0.2](/filings/0001628280-26-046138.md) | [0.2 d](/filings/0001628280-26-067038.md) | [0.1](/filings/0001628280-26-001450.md) | [0.2](/filings/0001628280-26-024148.md) | [0.3](/filings/0001628280-26-046138.md) | [0.4 d](/filings/0001628280-26-067038.md) | | Diluted EPS | $ per share | [1.47](/filings/0001628280-25-001058.md) | [7.31](/filings/0001628280-25-017004.md) | [1.06](/filings/0001628280-25-033410.md) | not reported | [0.88](/filings/0001628280-26-001450.md) | [1.06](/filings/0001628280-26-024148.md) | [2.03](/filings/0001628280-26-046138.md) | not reported | [1.35](/filings/0001628280-26-001450.md) | [2.08](/filings/0001628280-26-024148.md) | [2.59](/filings/0001628280-26-046138.md) | not reported | | Basic EPS | $ per share | [1.49](/filings/0001628280-25-001058.md) | [7.41](/filings/0001628280-25-017004.md) | [1.08](/filings/0001628280-25-033410.md) | not reported | [0.89](/filings/0001628280-26-001450.md) | [1.07](/filings/0001628280-26-024148.md) | [2.05](/filings/0001628280-26-046138.md) | not reported | [1.37](/filings/0001628280-26-001450.md) | [2.10](/filings/0001628280-26-024148.md) | [2.61](/filings/0001628280-26-046138.md) | not reported | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: not reported - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) | FY2026 (2026-08-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [1.6](/filings/0001193125-24-004852.md) | [2.6](/filings/0001628280-24-014951.md) | [2.5](/filings/0001628280-24-031429.md) | [2.2](/filings/0001628280-25-045293.md) | [2.1](/filings/0001628280-25-001058.md) | [1.6](/filings/0001628280-25-017004.md) | [1.5](/filings/0001628280-25-033410.md) | [1.9](/filings/0001628280-26-067038.md) | [1.6](/filings/0001628280-26-001450.md) | [1.8](/filings/0001628280-26-024148.md) | [1.4](/filings/0001628280-26-046138.md) | [1.7](/filings/0001628280-26-067038.md) | | Current assets | $bn | [14.7](/filings/0001193125-24-004852.md) | [12.5](/filings/0001628280-24-014951.md) | [12.9](/filings/0001628280-24-031429.md) | [12.8](/filings/0001628280-25-045293.md) | [13.2](/filings/0001628280-25-001058.md) | [12.6](/filings/0001628280-25-017004.md) | [13.8](/filings/0001628280-25-033410.md) | [13.7](/filings/0001628280-26-067038.md) | [14.4](/filings/0001628280-26-001450.md) | [15.0](/filings/0001628280-26-024148.md) | [18.2](/filings/0001628280-26-046138.md) | [21.5](/filings/0001628280-26-067038.md) | | Total assets | $bn | [19.4](/filings/0001193125-24-004852.md) | [17.1](/filings/0001628280-24-014951.md) | [17.4](/filings/0001628280-24-031429.md) | [17.4](/filings/0001628280-25-045293.md) | [17.8](/filings/0001628280-25-001058.md) | [17.4](/filings/0001628280-25-017004.md) | [18.6](/filings/0001628280-25-033410.md) | [18.5](/filings/0001628280-26-067038.md) | [19.3](/filings/0001628280-26-001450.md) | [20.6](/filings/0001628280-26-024148.md) | [23.8](/filings/0001628280-26-046138.md) | [27.4](/filings/0001628280-26-067038.md) | | Current liabilities | $bn | [13.0](/filings/0001193125-24-004852.md) | [10.7](/filings/0001628280-24-014951.md) | [11.4](/filings/0001628280-24-031429.md) | [11.8](/filings/0001628280-25-045293.md) | [12.4](/filings/0001628280-25-001058.md) | [12.3](/filings/0001628280-25-017004.md) | [14.0](/filings/0001628280-25-033410.md) | [13.7](/filings/0001628280-26-067038.md) | [14.5](/filings/0001628280-26-001450.md) | [14.8](/filings/0001628280-26-024148.md) | [18.5](/filings/0001628280-26-046138.md) | [21.7](/filings/0001628280-26-067038.md) | | Total liabilities | $bn | [16.9](/filings/0001193125-24-004852.md) | [14.5](/filings/0001628280-24-014951.md) | [15.2](/filings/0001628280-24-031429.md) | [15.6](/filings/0001628280-25-045293.md) | [16.2](/filings/0001628280-25-001058.md) | [16.0](/filings/0001628280-25-017004.md) | [17.3](/filings/0001628280-25-033410.md) | [17.0](/filings/0001628280-26-067038.md) | [17.9](/filings/0001628280-26-001450.md) | [19.3](/filings/0001628280-26-024148.md) | [22.5](/filings/0001628280-26-046138.md) | [25.8](/filings/0001628280-26-067038.md) | | Long-term debt | $bn | [2.9](/filings/0001193125-24-004852.md) | [2.9](/filings/0001628280-24-014951.md) | [2.9](/filings/0001628280-24-031429.md) | [2.9](/filings/0001628280-25-045293.md) | [2.9](/filings/0001628280-25-001058.md) | [2.9](/filings/0001628280-25-017004.md) | [2.4](/filings/0001628280-25-033410.md) | [2.4](/filings/0001628280-26-067038.md) | [2.4](/filings/0001628280-26-001450.md) | [3.4](/filings/0001628280-26-024148.md) | [2.9](/filings/0001628280-26-046138.md) | [2.9](/filings/0001628280-26-067038.md) | | Current portion of debt | $bn | [0.0](/filings/0001193125-24-004852.md) | [0.0](/filings/0001628280-24-014951.md) | [0.0](/filings/0001628280-24-031429.md) | [0.0](/filings/0001628280-25-045293.md) | [0.0](/filings/0001628280-25-001058.md) | [0.0](/filings/0001628280-25-017004.md) | [0.5](/filings/0001628280-25-033410.md) | [0.5](/filings/0001628280-26-067038.md) | [0.5](/filings/0001628280-26-001450.md) | [0.5](/filings/0001628280-26-024148.md) | [0.5](/filings/0001628280-26-046138.md) | [0.5](/filings/0001628280-26-067038.md) | | Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $bn | [2.5](/filings/0001193125-24-004852.md) | [2.7](/filings/0001628280-24-014951.md) | [2.3](/filings/0001628280-24-031429.md) | [1.7](/filings/0001628280-25-045293.md) | [1.6](/filings/0001628280-25-001058.md) | [1.4](/filings/0001628280-25-017004.md) | [1.3](/filings/0001628280-25-033410.md) | [1.5](/filings/0001628280-26-067038.md) | [1.3](/filings/0001628280-26-001450.md) | [1.3](/filings/0001628280-26-024148.md) | [1.3](/filings/0001628280-26-046138.md) | [1.6](/filings/0001628280-26-067038.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q4 FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) | Q4 FY2026 (2026-08-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [448](/filings/0001628280-25-001058.md) | [218 d](/filings/0001628280-25-017004.md) | [515 d](/filings/0001628280-25-033410.md) | [535 d](/filings/0001628280-26-067038.md) | [312](/filings/0001628280-26-001450.md) | [334 d](/filings/0001628280-26-024148.md) | [406 d](/filings/0001628280-26-046138.md) | [588 d](/filings/0001628280-26-067038.md) | [323](/filings/0001628280-26-001450.md) | [411 d](/filings/0001628280-26-024148.md) | [535 d](/filings/0001628280-26-046138.md) | [733 d](/filings/0001628280-26-067038.md) | | Capital expenditure | $m | [288](/filings/0001628280-25-001058.md) | [266 d](/filings/0001628280-25-017004.md) | [106 d](/filings/0001628280-25-033410.md) | [124 d](/filings/0001628280-26-067038.md) | [97.0](/filings/0001628280-26-001450.md) | [116 d](/filings/0001628280-26-024148.md) | [86.0 d](/filings/0001628280-26-046138.md) | [169 d](/filings/0001628280-26-067038.md) | [95.0](/filings/0001628280-26-001450.md) | [103 d](/filings/0001628280-26-024148.md) | [184 d](/filings/0001628280-26-046138.md) | [246 d](/filings/0001628280-26-067038.md) | | Dividends paid | $m | [12.0](/filings/0001628280-25-001058.md) | [10.0 d](/filings/0001628280-25-017004.md) | [10.0 d](/filings/0001628280-25-033410.md) | [10.0 d](/filings/0001628280-26-067038.md) | [10.0](/filings/0001628280-26-001450.md) | [9.0 d](/filings/0001628280-26-024148.md) | [9.0 d](/filings/0001628280-26-046138.md) | [8.0 d](/filings/0001628280-26-067038.md) | [10.0](/filings/0001628280-26-001450.md) | [8.0 d](/filings/0001628280-26-024148.md) | [9.0 d](/filings/0001628280-26-046138.md) | [8.0 d](/filings/0001628280-26-067038.md) | | Share repurchases | $m | [500](/filings/0001628280-25-001058.md) | [825 d](/filings/0001628280-25-017004.md) | [499 d](/filings/0001628280-25-033410.md) | [676 d](/filings/0001628280-26-067038.md) | [232](/filings/0001628280-26-001450.md) | [404 d](/filings/0001628280-26-024148.md) | [339 d](/filings/0001628280-26-046138.md) | [25.0 d](/filings/0001628280-26-067038.md) | [300](/filings/0001628280-26-001450.md) | [300 d](/filings/0001628280-26-024148.md) | [291 d](/filings/0001628280-26-046138.md) | [169 d](/filings/0001628280-26-067038.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2022-11-30) | Q2 FY2023 (2023-02-28) | Q3 FY2023 (2023-05-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [138](/filings/0001193125-24-004852.md) | [136](/filings/0001628280-24-014951.md) | [135](/filings/0001628280-24-031429.md) | [132](/filings/0001628280-25-001058.md) | [127](/filings/0001628280-25-017004.md) | [122](/filings/0001628280-25-033410.md) | [114](/filings/0001628280-26-001450.md) | [111](/filings/0001628280-26-024148.md) | [109](/filings/0001628280-26-046138.md) | [108](/filings/0001628280-26-001450.md) | [107](/filings/0001628280-26-024148.md) | [107](/filings/0001628280-26-046138.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 102,974,470 at 2026-10-20, from the cover of the [10-K filed 2026-10-23](/filings/0001628280-26-067038.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.